^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Non Small Cell Lung Cancer
    Drug:Bavencio (avelumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Lung Cancer
    Title:

    Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial

    Published date:
    02/06/2021
    Excerpt:
    In the JAVELIN Lung 200 trial, avelumab showed clinical activity as second-line treatment for patients with advanced NSCLC.
    DOI:
    10.1016/j.lungcan.2021.01.026
    Trial ID:
    JAVELIN Lung 200t